DC Field | Value | Language |
dc.contributor.author | Perekhoda, Lina | |
dc.contributor.author | Georgiyants, Victoria | |
dc.contributor.author | Yeromina, Hanna | |
dc.contributor.author | Drapak, Iryna | |
dc.contributor.author | Lubenets, Vira | |
dc.contributor.author | Ieromina, Zinaida | |
dc.contributor.author | Sych, Irina | |
dc.contributor.author | Severina, Hanna | |
dc.contributor.author | Demchenko, Anatoly | |
dc.date.accessioned | 2020-12-30T08:53:17Z | - |
dc.date.available | 2020-12-30T08:53:17Z | - |
dc.date.created | 2020-01-24 | |
dc.date.issued | 2020-01-24 | |
dc.identifier.citation | The Synthesis and In Silico Antihypertensive Activity Prognosis of New Mannich Bases Containing the 1,2,4-Triazole Moiety / Lina Perekhoda, Victoria Georgiyants, Hanna Yeromina, Iryna Drapak, Vira Lubenets, Zinaida Ieromina, Irina Sych, Hanna Severina, Anatoly Demchenko // Chemistry & Chemical Technology. — Lviv : Lviv Politechnic Publishing House, 2020. — Vol 14. — No 2. — P. 214–220. | |
dc.identifier.uri | https://ena.lpnu.ua/handle/ntb/55783 | - |
dc.description.abstract | У рамках наших постійних досліджень щодо
потенційних антигіпертензивних агентів серед похідних
морфоліну та піперидину було розроблено та синтезовано 10
нових цільових сполук, що містять 1,2,4-тріазольний та морфоліновий або піперидиновий фрагменти. Проведені докінгові
дослідження з метою пошуку біологічно активних речовин
антигіпертензивної дії. Результати in silico досліджень
свідчать, що всі синтезовані сполуки є перспективними інгібіторами ангіотензинперетворюючого ферменту і належать до
4 та 5 класів токсичності згідно класифікації OECР. | |
dc.description.abstract | As a part of our continuous research on potential
antihypertensive agents among morpholine and piperidine
derivatives, 10 novel target compounds containing
1,2,4-triazole and morpholine or piperidine moieties have
been designed and synthesized, and the docking studies
have been conducted in order to find biologically active
substances with the antihypertensive activity. The in silico
studies have shown that all compounds synthesized are
promising angiotensin converting enzyme inhibitors and
belong to the toxicity class 4 and 5 according to the
classification of chemicals by the OECD project. | |
dc.format.extent | 214-220 | |
dc.language.iso | en | |
dc.publisher | Видавництво Львівської політехніки | |
dc.publisher | Lviv Politechnic Publishing House | |
dc.relation.ispartof | Chemistry & Chemical Technology, 2 (14), 2020 | |
dc.relation.uri | https://doi.org/10.1111/cbdd.12520 | |
dc.relation.uri | https://doi.org/10.3897/pharmacia.66.e35083 | |
dc.relation.uri | https://doi.org/10.5958/0974-360X.2015.00100.6 | |
dc.relation.uri | https://doi.org/10.1002/med.21634 | |
dc.relation.uri | https://doi.org/10.1016/j.ejmech.2019.05.056 | |
dc.relation.uri | https://doi.org/10.1016/j.bmc.2015.09.034 | |
dc.relation.uri | https://doi.org/10.3390/molecules23071559 | |
dc.relation.uri | https://doi.org/10.1016/j.bmc.2013.10.017 | |
dc.relation.uri | https://doi.org/10.2174/092986712803414213 | |
dc.relation.uri | http://accelrys.com/ | |
dc.relation.uri | http://www.way2drug.com/gusar/acutoxpredict.html | |
dc.relation.uri | https://doi.org/10.5958/0974-360X.2019.00846.1 | |
dc.relation.uri | https://doi.org/10.1074/jbc.M110.167866 | |
dc.relation.uri | https://doi.org/10.1021/ml4004588 | |
dc.relation.uri | http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformati | |
dc.subject | основи Манніха | |
dc.subject | 1 | |
dc.subject | 2 | |
dc.subject | 4-тріазол | |
dc.subject | синтез | |
dc.subject | антигіпертензивна активність | |
dc.subject | прогноз in silico | |
dc.subject | докінгові дослідження | |
dc.subject | Mannich bases | |
dc.subject | 1 | |
dc.subject | 2 | |
dc.subject | 4-triazole | |
dc.subject | synthesis | |
dc.subject | antihypertensive activity | |
dc.subject | in silico prognosis | |
dc.subject | docking studies | |
dc.title | The Synthesis and In Silico Antihypertensive Activity Prognosis of New Mannich Bases Containing the 1,2,4-Triazole Moiety | |
dc.title.alternative | Синтез та in silico прогноз антигіпертензивної активності нових основ Манніха, що містять фрагмент 1,2,4-тріазолу | |
dc.type | Article | |
dc.rights.holder | © Національний університет “Львівська політехніка”, 2020 | |
dc.rights.holder | © Perekhoda L., Georgiyants V., Yeromina H., Drapak I., Lubenets V., Ieromina Z., Sych I., Severina H., Demchenko A., 2020 | |
dc.contributor.affiliation | National University of Pharmacy | |
dc.contributor.affiliation | Danylo Halytsky Lviv National Medical University | |
dc.contributor.affiliation | Lviv National Polytechnic University | |
dc.contributor.affiliation | National Academy of Medical Sciences | |
dc.contributor.affiliation | Nizhyn Mykola Gogol State University | |
dc.format.pages | 7 | |
dc.identifier.citationen | The Synthesis and In Silico Antihypertensive Activity Prognosis of New Mannich Bases Containing the 1,2,4-Triazole Moiety / Lina Perekhoda, Victoria Georgiyants, Hanna Yeromina, Iryna Drapak, Vira Lubenets, Zinaida Ieromina, Irina Sych, Hanna Severina, Anatoly Demchenko // Chemistry & Chemical Technology. — Lviv : Lviv Politechnic Publishing House, 2020. — Vol 14. — No 2. — P. 214–220. | |
dc.identifier.doi | doi.org/10.23939/chcht14.02.214 | |
dc.relation.references | [1] Kang D., Fang Z., Huang B. et al.: Chem. Biol. Drug Design, 2015, 86, 568. https://doi.org/10.1111/cbdd.12520 | |
dc.relation.references | [2] Drapak І., Zimenkovsky B., Perekhoda L. et al.: Pharmacia, 2019, 66, 33. https://doi.org/10.3897/pharmacia.66.e35083 | |
dc.relation.references | [3] Ueda Y., Timothy P., Wang I. et al.: Pat. US 8461333 B2, Publ. Jun. 11, 2013. | |
dc.relation.references | [4] Yradjan M., Yradjan N., Paronykjan R., Stepanjan H.: KhimikoFarmacevt. Zh., 2010, 44, 11. | |
dc.relation.references | [5] Klen E., Makarova N., Chalyullyn F. et al.: Bashkirsky Khim. Zh., 2008, 15, 112. | |
dc.relation.references | [6]Jakhmola V., Jawla S., Mishra R.: Acta Sci. Pharm. Sci., 2018, 2, 02. | |
dc.relation.references | [7] Al-Ghorbani M., Begum B. et al.: J. Chem. Pharm. Res., 2015, 8, 611. https://doi.org/10.5958/0974-360X.2015.00100.6 | |
dc.relation.references | [8] Kourounakis A., Xanthopoulos D., Tzara A.: Med. Res. Rev., 2020, 40, 709. https://doi.org/10.1002/med.21634 | |
dc.relation.references | [9] Yan X., Wang Z., Qi P. et al.: Eur. J. Med. Chem., 2019, 177, 425. https://doi.org/10.1016/j.ejmech.2019.05.056 | |
dc.relation.references | [10] Ladopoulou E., Matralis A., Nikitakis A., Kourounakis A.: Bioorg. Med. Chem., 2015, 23, 7015. https://doi.org/10.1016/j.bmc.2015.09.034 | |
dc.relation.references | [11] Mytnyk Z., Kolesnyk Ju.: Zaporozhsky Med. Zh., 2010, 12, 79. | |
dc.relation.references | [12] Bhat M., Al-Omar M., Ghabbour H., Naglah A.: Molecules, 2018, 23, 1559. https://doi.org/10.3390/molecules23071559 | |
dc.relation.references | [13] Manjusha R., Begum S., Begum A., Bharathi K.: Asian J. Pharm. Clinical Res., 2018, 11, 66. https://doi.org/10.3390/molecules23071559 | |
dc.relation.references | [14] Kaplaushenko A.: Naukovyi Zh. MOZ Ukrainy, 2013, 3, 152. | |
dc.relation.references | [15] Sahu N., Sahu J., Kaushik A.: Curr. Res. Pharm. Sci., 2013, 3, 108. | |
dc.relation.references | [16] Malani A., Makwana A., Makwana H.: Moroccan J. Chem., 2017, 5, 41. | |
dc.relation.references | [17] Liu J., Liu Q., Yang X. et al.: Bioorgan. Med. Chem., 2013, 21, 7742. https://doi.org/10.1016/j.bmc.2013.10.017 | |
dc.relation.references | [18] Zhou C.-H., Wang Y.: Current Medicinal Chemistry, 2012, 19, 239. https://doi.org/10.2174/092986712803414213 | |
dc.relation.references | [19] http://accelrys.com/ | |
dc.relation.references | [20] http://www.way2drug.com/gusar/acutoxpredict.html | |
dc.relation.references | [21] Drapak I., Suleiman M., Protopopov M. et al.: Res. J. Pharm. Technol., 2019, 12, 4889. https://doi.org/10.5958/0974-360X.2019.00846.1 | |
dc.relation.references | [22] Anthony C., Corradi H., Schwager S. et al.: J. Biol. Chem., 2010, 285, 35685. https://doi.org/10.1074/jbc.M110.167866 | |
dc.relation.references | [23] Kramer G., Mohd A., Schwager S. et al.: ACS Med. Chem. Lett., 2014, 5, 346. https://doi.org/10.1021/ml4004588 | |
dc.relation.references | [24] http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformati onforpatientsandproviders/ucm102981.htm | |
dc.relation.referencesen | [1] Kang D., Fang Z., Huang B. et al., Chem. Biol. Drug Design, 2015, 86, 568. https://doi.org/10.1111/cbdd.12520 | |
dc.relation.referencesen | [2] Drapak I., Zimenkovsky B., Perekhoda L. et al., Pharmacia, 2019, 66, 33. https://doi.org/10.3897/pharmacia.66.e35083 | |
dc.relation.referencesen | [3] Ueda Y., Timothy P., Wang I. et al., Pat. US 8461333 B2, Publ. Jun. 11, 2013. | |
dc.relation.referencesen | [4] Yradjan M., Yradjan N., Paronykjan R., Stepanjan H., KhimikoFarmacevt. Zh., 2010, 44, 11. | |
dc.relation.referencesen | [5] Klen E., Makarova N., Chalyullyn F. et al., Bashkirsky Khim. Zh., 2008, 15, 112. | |
dc.relation.referencesen | [6]Jakhmola V., Jawla S., Mishra R., Acta Sci. Pharm. Sci., 2018, 2, 02. | |
dc.relation.referencesen | [7] Al-Ghorbani M., Begum B. et al., J. Chem. Pharm. Res., 2015, 8, 611. https://doi.org/10.5958/0974-360X.2015.00100.6 | |
dc.relation.referencesen | [8] Kourounakis A., Xanthopoulos D., Tzara A., Med. Res. Rev., 2020, 40, 709. https://doi.org/10.1002/med.21634 | |
dc.relation.referencesen | [9] Yan X., Wang Z., Qi P. et al., Eur. J. Med. Chem., 2019, 177, 425. https://doi.org/10.1016/j.ejmech.2019.05.056 | |
dc.relation.referencesen | [10] Ladopoulou E., Matralis A., Nikitakis A., Kourounakis A., Bioorg. Med. Chem., 2015, 23, 7015. https://doi.org/10.1016/j.bmc.2015.09.034 | |
dc.relation.referencesen | [11] Mytnyk Z., Kolesnyk Ju., Zaporozhsky Med. Zh., 2010, 12, 79. | |
dc.relation.referencesen | [12] Bhat M., Al-Omar M., Ghabbour H., Naglah A., Molecules, 2018, 23, 1559. https://doi.org/10.3390/molecules23071559 | |
dc.relation.referencesen | [13] Manjusha R., Begum S., Begum A., Bharathi K., Asian J. Pharm. Clinical Res., 2018, 11, 66. https://doi.org/10.3390/molecules23071559 | |
dc.relation.referencesen | [14] Kaplaushenko A., Naukovyi Zh. MOZ Ukrainy, 2013, 3, 152. | |
dc.relation.referencesen | [15] Sahu N., Sahu J., Kaushik A., Curr. Res. Pharm. Sci., 2013, 3, 108. | |
dc.relation.referencesen | [16] Malani A., Makwana A., Makwana H., Moroccan J. Chem., 2017, 5, 41. | |
dc.relation.referencesen | [17] Liu J., Liu Q., Yang X. et al., Bioorgan. Med. Chem., 2013, 21, 7742. https://doi.org/10.1016/j.bmc.2013.10.017 | |
dc.relation.referencesen | [18] Zhou C.-H., Wang Y., Current Medicinal Chemistry, 2012, 19, 239. https://doi.org/10.2174/092986712803414213 | |
dc.relation.referencesen | [19] http://accelrys.com/ | |
dc.relation.referencesen | [20] http://www.way2drug.com/gusar/acutoxpredict.html | |
dc.relation.referencesen | [21] Drapak I., Suleiman M., Protopopov M. et al., Res. J. Pharm. Technol., 2019, 12, 4889. https://doi.org/10.5958/0974-360X.2019.00846.1 | |
dc.relation.referencesen | [22] Anthony C., Corradi H., Schwager S. et al., J. Biol. Chem., 2010, 285, 35685. https://doi.org/10.1074/jbc.M110.167866 | |
dc.relation.referencesen | [23] Kramer G., Mohd A., Schwager S. et al., ACS Med. Chem. Lett., 2014, 5, 346. https://doi.org/10.1021/ml4004588 | |
dc.relation.referencesen | [24] http://www.fda.gov/drugs/drugsafety/postmarketdrugsafetyinformati onforpatientsandproviders/ucm102981.htm | |
dc.citation.volume | 14 | |
dc.citation.issue | 2 | |
dc.citation.spage | 214 | |
dc.citation.epage | 220 | |
dc.coverage.placename | Львів | |
dc.coverage.placename | Lviv | |
Appears in Collections: | Chemistry & Chemical Technology. – 2020. – Vol. 14, No. 2
|